ALNY - ALNYLAM PHARMACEUTICALS, INC.

QQQ $ 431.01 $ 6.55 (1.54 %)

DIA $ 382.27 $ 1.39 (0.36 %)

SPY $ 508.26 $ 4.77 (0.95 %)

TLT $ 88.26 $ 0.46 (0.52 %)

GLD $ 216.60 $ 0.70 (0.32 %)

Previous Close

$ 143.31

Open

$ 143.63

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 143.01 - $ 145.94

52 Week Range

$ 141.98 - $ 218.88

Volume

479,139

Average Volume

Market Cap

17.9B

Beta (5Y Monthly)

$ 0.72

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	02-15-2024	12-31-2023	10-K
2	11-02-2023	09-30-2023	10-Q
3	08-03-2023	06-30-2023	10-Q
4	05-04-2023	03-31-2023	10-Q
5	02-23-2023	12-31-2022	10-K
6	10-27-2022	09-30-2022	10-Q
7	07-28-2022	06-30-2022	10-Q
8	04-28-2022	03-31-2022	10-Q
9	02-10-2022	12-31-2021	10-K
10	10-28-2021	09-30-2021	10-Q
11	08-03-2021	06-30-2021	10-Q
12	04-29-2021	03-31-2021	10-Q
13	02-11-2021	12-31-2020	10-K
14	11-05-2020	09-30-2020	10-Q
15	08-06-2020	06-30-2020	10-Q
16	05-06-2020	03-31-2020	10-Q
17	02-13-2020	12-31-2019	10-K
18	10-31-2019	09-30-2019	10-Q
19	08-06-2019	06-30-2019	10-Q
20	05-02-2019	03-31-2019	10-Q
21	02-14-2019	12-31-2018	10-K
22	11-07-2018	09-30-2018	10-Q
23	08-02-2018	06-30-2018	10-Q
24	05-04-2018	03-31-2018	10-Q
25	02-15-2018	12-31-2017	10-K
26	11-07-2017	09-30-2017	10-Q
27	08-09-2017	06-30-2017	10-Q
28	05-05-2017	03-31-2017	10-Q
29	02-15-2017	12-31-2016	10-K
30	11-03-2016	09-30-2016	10-Q
31	08-04-2016	06-30-2016	10-Q
32	05-04-2016	03-31-2016	10-Q
33	02-12-2016	12-31-2015	10-K
34	11-09-2015	09-30-2015	10-Q
35	08-07-2015	06-30-2015	10-Q
36	05-08-2015	03-31-2015	10-Q
37	02-13-2015	12-31-2014	10-K
38	11-06-2014	09-30-2014	10-Q
39	08-08-2014	06-30-2014	10-Q
40	05-09-2014	03-31-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

how-is-the-market-feeling-about-alnylam-pharmaceuticals

How Is The Market Feeling About Alnylam Ph...
04/19/2024 18:30:25

10-health-care-stocks-with-whale-alerts-in-todays-session

10 Health Care Stocks With Whale Alerts In...
04/09/2024 17:35:25

analysts-express-confidence-in-alnylams-hypertension-drug-despite-mixed-trial-data

Analysts Express Confidence in Alnylam's H...
04/08/2024 18:37:35

The latest findings from Alnylam Pharmaceuticals' KARDIA-2 Phase 2 study are on zilebesiran's efficacy and safety in tr...

Reported Sunday, Alnylam Presents Results ...
04/08/2024 06:56:44

Study Met Primary Endpoint Demonstrating Clinically Significant Additive Reductions in Ambulatory Systolic Blood Pressure of ...

100-invested-in-alnylam-pharmaceuticals-15-years-ago-would-be-worth-this-much-today

$100 Invested In Alnylam Pharmaceuticals 1...
04/02/2024 19:00:22

BMO Capital Maintains Outperform on Alnyla...
03/27/2024 14:07:17

BMO Capital analyst Kostas Biliouris maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and maintains $234 pr...

heres-how-much-you-would-have-made-owning-alnylam-pharmaceuticals-stock-in-the-last-15-years

Here's How Much You Would Have Made Owning...
03/18/2024 14:30:38

rochealnylam-blood-pressure-drug-aces-in-mid-stage-trial-analyst-says-zilebesiran-as-promising-opportunity-in-addressing-global-hypertension-challenges

Roche/Alnylam Blood Pressure Drug Aces In ...
03/05/2024 19:38:20

Alnylam's KARDIA-2 Phase 2 study on zilebesiran, an RNAi therapeutic for hypertension. Clinically significant reductions in...

HC Wainwright & Co. Reiterates Buy on Alny...
03/05/2024 17:05:23

HC Wainwright & Co. analyst Patrick Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and maintains $...

Alnylam And Roche Initiated KARDIA-3 Phase...
03/05/2024 12:42:31

Alnylam/Roche Report KARDIA-2 Topline Stud...
03/05/2024 12:40:59

10-health-care-stocks-whale-activity-in-todays-session

10 Health Care Stocks Whale Activity In To...
02/29/2024 17:35:24

heres-how-much-100-invested-in-alnylam-pharmaceuticals-15-years-ago-would-be-worth-today

Here's How Much $100 Invested In Alnylam P...
02/28/2024 21:00:37

Cantor Fitzgerald Maintains Neutral on Aln...
02/23/2024 17:09:21

Cantor Fitzgerald analyst Olivia Brayer maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Neutral and lowers the price ...

RBC Capital Reiterates Outperform on Alnyl...
02/21/2024 14:54:10

RBC Capital analyst Luca Issi reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and maintains $235 price ta...

Cantor Fitzgerald Reiterates Neutral on Al...
02/20/2024 17:31:01

Cantor Fitzgerald analyst Olivia Brayer reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Neutral and maintains $165 p...

RBC Capital Reiterates Outperform on Alnyl...
02/20/2024 15:23:22

RBC Capital analyst Luca Issi reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and maintains $235 price ta...

Goldman Sachs Downgrades Alnylam Pharmaceu...
02/16/2024 17:00:34

RBC Capital Reiterates Outperform on Alnyl...
02/16/2024 16:53:08

RBC Capital analyst Luca Issi reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and maintains $235 price ta...

Chardan Capital Maintains Buy on Alnylam P...
02/16/2024 13:14:00

Chardan Capital analyst Keay Nakae maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target fr...